Forum Archive Index - November 2000

["David Reid" <aspex@ix.net.nz>]

Some comments re Genesis and psoriasis.

Are they depending on this product?   

Some extracts from other research on companies in competition:

 

1.Bioglan specialises in developing treatments for dermatology problems such as acne, psoriasis and eczema. This is a relatively flat global market growing at 5% per annum, but Bioglan has made a success of it. Dermatology represents 42% of annual turnover and 62% of product sales.

 

2..SR Pharma........announces that its US licensing partner, Corixa Corporation, and Medicis Pharmaceutical Corporation have announced that the companies have entered into a multi-year development, commercialisation and licence agreement covering PVAC(TM) treatment for psoriasis. The agreement provides Medicis with exclusive rights to PVAC treatment in the United States and Canada. Corixa will be responsible for development and manufacturing, and Medicis will be responsible for commercialisation and distribution. PVAC treatment is based on a proprietary process and formulation derived from heat-killed Mycobacterium vaccae. SR Pharma holds a broad patent position for the use of Mycobacterium vaccae and other Mycobacterium vaccae-derived products to treat autoimmune diseases. PVAC treatment is currently in Phase II clinical trials in the USA, the Philippines and Brazil, for the treatment of moderate to severe psoriasis. Under the terms of the agreement, Medicis will pay Corixa licence fees, research funding and milestone payments of up to $107m. Upon effectiveness, Corixa will receive a non-refundable payment of $17m with additional potential development milestone payments of $35m, and commercialisation and cumulative net sales threshold milestone payments of $55m. Additionally, upon commercial sale of the product, Medicis will purchase inventory from Corixa and pay a royalty on net sales of the product. The effectiveness of the collaboration agreement between Corixa and Medicis is subject to certain customary conditions, including any required approval of the transaction by applicable government agencies. Corixa has an existing partnership in Japan for PVAC treatment, with Zenyaku Kogyo Pharmaceuticals, and is seeking to add marketing partners for Europe and the rest of the world. Under the terms of its agreement with Corixa, SR Pharma will receive a series of payments based on the licence fees, milestone payments and royalties made to Corixa by Medicis.

 

Are these direct competitors???

David Reid